Press release
Publishing on April 21, 2026 at 2:00 pm local time (EEST)
A peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy waiting lists
The new peer-reviewed publication in the prestigious journal Helicobacter (2026) confirms the clinical utility of GastroPanel® as a non-invasive triage tool for gastric cancer risk stratification.
GastroPanel® combines biomarker-based testing with risk algorithms, enabling the safe prioritization of patients for endoscopy and reducing unnecessary procedures. In real-world implementation in Molina, Chile, the approach resulted in an 87% reduction in endoscopy waiting lists and ensured rapid access to endoscopy for high- and intermediate-risk patients.
“This is a highly significant milestone for Biohit and for global healthcare systems”, says Jussi Hahtela, CEO of Biohit Oyj. “We now have peer-reviewed evidence showing that endoscopy waiting lists can be reduced by up to 87% without compromising patient safety. Scarcity of healthcare resources is a global challenge, and GastroPanel® offers a practical, evidence-based solution to allocate those resources more effectively while improving early detection of gastric cancer.”
The results reinforce GastroPanel®’s position as a scalable, evidence-based solution for improving early detection of gastric cancer and enabling more efficient allocation of healthcare resources worldwide.
Additional information:
Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and it has a subsidiary in the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.